Verrica Pharmaceuticals Inc. Increase (Decrease) in Accrued Liabilities
Verrica Pharmaceuticals Inc. (VRCA) reported Increase (Decrease) in Accrued Liabilities of $1.39 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2021-03-17
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-12-31 was -$1.45M, a 946.78% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-09-30 was $88.00K, a 91.30% increase year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-06-30 was $1.14M, a 53.84% increase year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-03-31 was $4.00K, a 96.30% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $1.39M.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for fiscal 2019 was -$213.00K, a 119.94% decline from fiscal 2018.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for fiscal 2018 was $1.07M, a 703.01% increase from fiscal 2017.
- Verrica Pharmaceuticals Inc. increase (decrease) in accrued liabilities for fiscal 2017 was $133.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.39M 10-K · filed 2021-03-17 | |||
| 2019-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$1.36M derived: sum of 2 quarters · filed 2021-03-17 | -$217.00K derived: sum of 3 quarters · filed 2021-03-17 | -$213.00K 10-K · filed 2021-03-17 |
| 2019-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.23M derived: sum of 2 quarters · filed 2019-11-06 | $1.24M 10-Q · filed 2019-11-06 | $1.41M derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.15M 10-Q · filed 2019-08-07 | $1.32M derived: sum of 3 quarters · filed 2020-03-13 | $1.36M derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-03-31 | $4.00K 10-Q · filed 2019-05-07 | $175.00K derived: sum of 2 quarters · filed 2020-03-13 | $221.00K derived: sum of 3 quarters · filed 2020-03-13 | $964.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $217.00K derived: sum of 2 quarters · filed 2020-03-13 | $960.00K derived: sum of 3 quarters · filed 2020-03-13 | $1.07M 10-K · filed 2020-03-13 |
| 2018-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $789.00K derived: sum of 2 quarters · filed 2019-11-06 | $897.00K 10-Q · filed 2019-11-06 | $1.05M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $743.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $851.00K 10-Q · filed 2019-08-07 | $1.01M derived: sum of 3 quarters · filed 2019-08-07 | $936.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $108.00K 10-Q · filed 2019-05-07 | $263.00K derived: sum of 2 quarters · filed 2019-05-07 | $193.00K derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $85.00K derived: sum of 2 quarters · filed 2019-03-07 | $133.00K 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$22.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $48.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |